Barinthus Biotherapeutics (BRNS) on Friday reported "encouraging" results from its ongoing phase 2b HBV003 trial for chronic hepatitis B.
The study, involving 121 participants, assessed VTP-300 in combination with a low dose of anti-PD1 antibody nivolumab, and new data shows eight participants achieved complete HBsAg loss, while two met the criteria for a functional cure, the clinical-stage biopharmaceutical company said.
Barinthus said the ongoing study data shows that stronger responses could occur in patients treated with the VTP-300 and nivolumab. Preliminary safety data also showed that the treatment was well-tolerated, with no treatment-related serious adverse events reported as of the data cutoff, the company said.
Shares of Barinthus Biotherapeutics were down more than 16% in recent Friday trading.
Price: 1.12, Change: -0.26, Percent Change: -18.84
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。